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Melanoma is one of the most aggressive types of cancer and resection of the tumour prior to dissemination of tumour cells is still the
most effective treatment. Therefore, early diagnosis of melanocytic lesions is important and identification of novel (molecular)
markers would be helpful to improve diagnosis. Moreover, better understanding of molecular targets involved in melanocytic
tumorigenesis could possibly lead to development of novel interventions. In this study, we used a custom made oligonucleotide array
containing 298 genes that were previously found to be differentially expressed in human melanoma cell lines 1F6 (rarely
metastasising) and Mel57 (frequently metastasising). We determined differential gene expression in human common nevocellular
nevus and melanoma metastasis lesions. By performing nine dye-swap array experiments, using individual as well as pooled
melanocytic lesions, a constant differential expression could be detected for 25 genes in eight out of nine or nine out of nine array
analyses. For at least nine of these genes, namely THBD, FABP7, H2AFJ, RRAGD, MYADM, HR, CKS2, NCK2 and GDF15, the
differential expression found by array analyses could be verified by semiquantitative and/or real-time quantitative RT–PCR. The genes
that we identified to be differentially expressed during melanoma progression could be potent targets for diagnostic, prognostic and/
or therapeutic interventions.
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Melanoma is a very aggressive type of tumour, as it metastasises
early in tumour progression. Due to its relative insensitivity to
systemic therapies, such as chemotherapy and radiation, the most
effective cure for melanoma patients nowadays remains surgical
excision of the tumour before onset of the metastatic growth
phase. This means that early diagnosis of melanocytic tumour
lesions is essential.
The molecular mechanisms underlying malignant transforma-
tion of melanocytes and melanoma tumour progression are not
very complete yet. Extensive analysis of molecular changes that
occur during tumour development may not only provide better
insight in melanocytic tumorigenesis, but additionally yield
valuable tools for clinical applications. Novel diagnostic and/or
prognostic markers and targets for (immuno-)therapy could be
identified by determining the differential gene expression in
different stages of melanoma progression.
For most microarray studies related to melanocytic tumori-
genesis, cell lines or fresh tumour cells that were cultured for some
passages were used to examine differential gene expression (Baldi
et al, 2003a; Dooley et al, 2003; Rumpler et al, 2003; Hoek et al,
2004). However, usage of these cells is not ideal, as culturing
conditions can influence the genetic expression. In a previous
study, we also determined differential gene expression in two
human melanoma cell lines, 1F6 and Mel57, showing distinct
metastatic behaviour after subcutaneous inoculation into nude
mice, by using high-density oligonucleotide array analyses
(Affymetrix) (Westphal et al, 1997; de Wit et al, 2002). We found
an up- or downregulation of 298 genes/ESTs among the more than
40000 genes that were analysed. In this study, we now used fresh
human melanocytic tumour lesions of different progression stages
to determine whether the previously identified genes remained
differentially expressed in the in vivo situation. This would
probably be more informative regarding involvement of the genes
in melanoma progression. Custom oligonucleotide arrays were
designed representing the 298 genes/ESTs and hybridisation was
performed using target probes derived from common nevocellular
nevus (NN) and melanoma metastasis (MM) samples. After array
analyses, differential gene expression was verified by semiquanti-
tative and real-time quantitative reverse transcriptase (RT)–PCR.
The reliability of our custom array analyses is discussed, next to
the putative involvement of the differentially expressed genes in
melanoma tumour progression and their potential significance as
new diagnostic/prognostic markers and/or targets for (immuno-)
therapy.
MATERIALS AND METHODS
Human tissue samples and cell lines
Human melanocytic tumour samples were obtained by resection of
the lesions at University Medical Centre (UMC) St Radboud
Received 25 October 2004; revised 5 April 2005; accepted 5 April 2005;
published online 17 May 2005
*Correspondence: Dr GNP van Muijen, Department of Pathology,
Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB
Nijmegen, The Netherlands; E-mail: g.vanmuijen@pathol.umcn.nl
British Journal of Cancer (2005) 92, 2249–2261
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sNijmegen (The Netherlands). This was all performed according to
local ethical guidelines and approved by the local regulatory
committee. After resection, all tissue samples were immediately
frozen in liquid nitrogen and stored at  801C until use.
Human melanoma cell lines, 1F6 and Mel57, were grown in
Dulbecco’s modified Eagle’s medium (DMEM) as described
previously (de Vries et al, 1996; Westphal et al, 1997).
Design and printing of custom oligonucleotide arrays
In a previous study, 298 genes/ESTs were identified showing
differential gene expression in two human melanoma cell lines,
1F6 and Mel57 (de Wit et al, 2002). For preparation of custom
arrays these genes/ESTs were selected, together with four house-
keeping genes, namely glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), phosphoglycerate kinase 1 (PGK1), porphobilinogen
deaminase (PBGD) and b-actin. Based on these genes/ESTs, 70-
mer amino-linked oligonucleotides were designed (Operon Tech-
nologies Inc., Qiagen, Alameda, CA, USA), complementary to the
30-side of the corresponding genes/ESTs. These oligonucleotides
were dissolved in spotting buffer (3  SSC, 1.5 M betaine) and
spotted in octaplicate onto UltraGAPS slides (Corning, New York,
USA) using the Prosys 5510TL arrayer (Genomic Solutions,
Huntingdon, Cambridgeshire, UK) (Figure 1). Additionally,
various controls, which provided information about the target
probe labelling efficiency, blocking, and nonspecific binding of the
arrays, were spotted onto the array. These controls included
oligonucleotides of various non-human species, Cot-1 repetitive
sequences, polyA sequences (SpotReport, Stratagene, La Jolla,
CA, USA), tRNA and spots containing only spotting buffer.
Supplementary array design data are available at the NCBI Gene
Expression Omnibus, GEO (www.ncbi.nlm.nih.gov/geo/).
RNA isolation
For total RNA extraction from tissue samples, at least 10 frozen
slices of 20mm thickness were collected in 1ml TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA). After the TRIzol method, total
RNA was subjected to an additional RNeasy (Qiagen, Hilden,
Germany) cleaning step. Concerning the cell lines, total RNA was
isolated from 10
7 cultured cells using the RNeasy mini kit
(Qiagen). All methods were performed conform the manufac-
turer’s protocol.
Target labelling, hybridisation and array analysis
Both direct and indirect labelling methods were used for labelling
of target probes. Using the CyScribe first-strand cDNA labelling kit
(Amersham Biosciences, Freiburg, Germany), cDNA was directly
labelled by incorporation of Cy3- and Cy5-dUTPs during a RT
reaction. We first isolated mRNA from 50mg of total RNA using
the Oligotex mRNA mini kit (Qiagen). The subsequent labelling
reaction was performed according to the manufacturer’s protocol.
For indirect labelling, 2mg of total RNA (ratio 28S/18S RNAs41)
were subjected to linear RNA amplification using the Amino Allyl
MessageAmp aRNA Kit (Ambion, Cambridgeshire, UK). During
this procedure, 5-(3-aminoally)-UTP was incorporated into the
amplified antisense RNA (aRNA). N-hydroxysuccinimidyl (NHS)
ester-derivitised reactive Cy3 and Cy5 dyes (Fluorolink Cy3/Cy5
Monofunctional Dye 5-Pack, Amersham Biosciences) were then
chemically coupled to 3mg of amino allyl aRNA. RNA amplifica-
tion as well as chemical labelling was performed according to the
instruction manual of the Amino Allyl MessageAmp aRNA Kit.
Cy3 and Cy5 dye incorporation was measured by spectro-
photomeric analyses at 550 and 650nm, respectively.
Prior to hybridisation, Cy3 and Cy5 labelled cDNA/aRNA
samples were mixed (1:1), together with 7mg Cot-1 DNA (Roche
Diagnostics) and 3mg polyA (Amersham Biosciences). After
precipitation, the sample was dissolved in 130ml of a hybridisation
solution containing 50% formamide, 10% dextran sulphate, 2 
SSC, 4% SDS, and 10mg/ml yeast tRNA (Invitrogen). Hybridisation
to our custom arrays and posthybridisation washing procedures
were performed using a GeneTAC Hybridization Station (Genomic
Solutions), according to the manufacturer’s protocols. In short, a
16h hybridisation with active circulation of the probe was followed
by five posthybridisation wash cycles in 50% formamide/2  SSC
at 451C and five wash cycles in PBS at 201C. The slides were briefly
washed in water and dried by centrifugation. In dye-swap
experiments, two replicate arrays were hybridised with similar
cDNA/aRNA samples, but with swapped dyes.
Arrays were scanned and imaged on an Affymetrix 428 scanner
(Affymetrix, Santa Clara, CA, USA) using the Affymetrix 428
scanner software package (version 1.0). Generally, the Cy5 dye
showed a higher fluorescence intensity than the Cy3 dye. There-
fore, scanning intensities used to image the individual dyes were
adjusted to obtain a Cy5/Cy3 ratio¼1 for the housekeeping genes
GAPDH and b-actin. To determine differential gene expression,
the acquired array images were first analysed visually (red or green
spots), but additionally GenePix Pro 4.0 software (Axon Instru-
ments, Union City, CA, USA) was used. In the latter, differential
gene expression was determined by comparing the median of the
pixel intensities minus the median local background (F-B) of Cy5
with that of Cy3. Spots displaying F-B values smaller than 100 for
both Cy dyes were excluded from further analysis. Alternatively,
differential gene expression was determined by transforming
median of ratios values (GenePix Pro 4.0) by taking the log2. All
octaplicate gene-specific spots were included in the analyses.
= Replicate spots
= Replicate blocks
Octaplicate gene-specific spots
Figure 1 Custom made oligonucleotide array design. 70-mer oligo’s,
corresponding to 298 genes that were previously found to be differentially
expressed in cell lines 1F6 and Mel57 and four additional housekeeping
genes, were spotted in octaplicate on UltraGAPS slides. The housekeeping
genes were randomly localised throughout the array. Additionally, various
other controls for labelling and hybridisation efficiency were present on the
array, such as oligo’s of non-human species, Cot-1 repetitive sequences,
polyA sequences and spots containing only spotting buffer.
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Expression Omnibus, GEO (www.ncbi.nlm.nih.gov/geo/).
Semiquantitative RT–PCR
Aliquots of 1 and 0.5mg of total RNA from cell lines and human
melanocytic tissue samples, respectively, were reverse-transcribed
using Moloney murine leukaemia virus reverse transcriptase
(M-MLV RT) (Promega, Madison, WI, USA). Apart from 200U
of M-MLV RT, the reaction mixture consisted of 250pmol of
random hexadeoxynucleotide primers (Roche Diagnostics GmbH,
Penzberg, Germany), 4ml of RT buffer (250mM Tris-HCl pH 8.3,
375mM KCl, 15mM MgCl2,5 0 m M DTT) and 4mlo f1 m M dNTPs
(Roche Diagnostics GmbH), completed with water to a final
volume of 20ml. This mixture was incubated 10min at 251C, 59min
at 421C and 5min at 951C. cDNA samples of human melanocytic
lesions were diluted 1:1 in water.
Generally, PCR amplification was carried out in a total volume
of 25ml containing 1ml reverse-transcribed cDNA, 2.5ml of PCR
buffer IV (20mM (NH4)2SO4,7 5 m M Tris/HCl pH 9.0 and 0.1%
Tween), 5pmol of each primer, 0.15U of Thermoperfectplus DNA
polymerase (Integro, Zaandam, The Netherlands) and the appro-
priate MgCl2 concentration. After 5min denaturation at 941C,
25/30 and 30/35 cycles of amplification were carried out for cell
lines and human melanocytic lesions, respectively: 45s at 941C,
45s at 591C, 1min at 721C, followed by a 5-min elongation step at
721C. Housekeeping genes GAPDH and b-actin that were used for
normalisation were amplified in 25/30 cycles independent of cDNA
origin. The primer sequences and MgCl2 concentrations used for
each single PCR reaction are shown in Table 1.
Real-time quantitative RT–PCR
To determine differential gene expression of fatty acid binding
protein 7 (FABP7, UniGeneID Hs.26770) and growth differentia-
tion factor 15 (GDF-15, UniGene ID Hs.296638) by real-time
quantitative RT–PCR (qPCR), we used Assays-on-Demand Gene
Expression Assays (Applied Biosystems, Cheshire, UK); assay ID
Hs00361426_m1 and Hs00171132_m1, respectively. These assays
consisted of a mix of unlabelled PCR primers and TaqMan MGB
probe (FAM dye-labelled). Additionally, for normalisation, Assays-
on-Demand Gene Expression Assay specific for GAPDH (assay ID
Hs99999905_m1) was selected. The efficiency of each assay was
tested in a cDNA dilution series. qPCR reactions were performed
in a total volume of 25ml, containing 2  TaqMan Universal PCR
Master Mix (Applied Biosystems), 20  Assays-on-Demand Gene
Expression Assay Mix and 12.5ng cDNA (similar cDNA samples
as were used for semiquantitative RT–PCR). All qPCRs were
performed in duplo and run in an ABI/PRISM 7700 Sequence
Detector System (Applied Biosystems) using the following condi-
tions: 501C for 2min, 951C for 10min, and 40 cycles of 951C for
15s, 601C for 1min. To quantify the relative changes in gene
expression of FABP7 and GDF15, we used the 2
-DDCT method
(Winer et al, 1999; Livak and Schmittgen, 2001), in which 1F6 and
Mel57 were selected as calibrator, respectively.
Sequence analyses
The specificity of PCR products was validated by sequence
analyses. Sequence reactions were performed with about 25ng
PCR product in addition of 10mM specific forward or reverse
primer, using the ABI PRISM 3700 DNA Analyser (Perkin-Elmer,
Applied Biosystems, Forster City, CA, USA).
Immunohistochemistry
Cell suspensions of human melanoma cell lines 1F6 and Mel57
were processed into AgarCyto’s as previously described (Kerstens
et al, 2000). 4mm sections of paraffin-embedded AgarCyto’s
and melanocytic tumour lesions were mounted on Superfrost
microscope slides. These sections were dewaxed in xylene and
rehydrated in a series of graded alcohols. To block endogenous
peroxidase activity, slides were incubated with 3% H2O2 for
20min. In contrast to immunohistochemical detection of
thrombomodulin (THBD), for GDF15 and FABP7 antigen retrieval
was essential; rehydrated slides were placed in citrate buffer (pH
6.0) and heated in a microwave oven to 971C at 850W for 5min.
This temperature was maintained with an additional 10min
heating at 350W. After cooling down to room temperature, the
sections were briefly washed with PBS. Next to AgarCyto sections,
Table 1 Primers used for semiquantitative RT–PCR analyses
Gene
symbol Primers
MgCl2
(mM)
THBD F: 50-GTGGACGGCGAGTGTGTG-30 1.5
R: 50-CAGAGGTAGCTAGTTTGGTTCAGG-30
GRCC10 F: 50-TCGTGCTGCCCGTGG-30 1.5
R: 50-AGGCTGGCGATCTCAGGAT-30
FABP7 F: 50-AACTTGTTCACATACAGAAATGGGAT-30 2.0
R: 50-AGAACATTTTTATGCCTTCTCA-30
H2AFJ F: 50-CGTGCTGCTGCCCAAGA-30 1.5
R: 50-TTGCGGGACGACCATGA-30
TYRP1 F: 50-CTTGGAAGATTATGATACCCTGGG-30 1.5
R: 50-GAGCGACATCCTGTGGTTCA-30
MYL6 F: 50-GAAGCGTTTGTGAGGCATATCC-30 2.0
R: 50-TAGATACAAAATTCACACAGGGAAAGG-30
D4S234E F: 50-TTCCTCACCTGCGTCGTCTT-30 1.5
R: 50-CGTAGTAGCTCTCCAAGCGTTCTG-30
CD74 F: 50-GAAGATCAGAAGCCAGTCATGG-30 1.5
R: 50-AGAGCTACCAGGATGGAAAAGC-30
C7orf20 F: 50-GCCGCTGCTTAACTTCATCTG-30 1.5
R: 50-GTCCTATGCGGTCGAGGTACTC-30
COL6A1 F: 50-GCGACGCACTCAAAAGCA-30 1.5
R: 50-GGTACTTATTCTCCTTCAGGTGGG-30
CGI-127 F: 50-GACCAACCGCTCAGAACTCATC-30 1.5
R: 50-AGCATGACCCGASTCTTGAACTT-30
RRAGD F: 50-ATTGACTTTTTTGACCCTACATTTGAC-30 1.5
R: 50-GCCAGGGCTTCCATGTAATC-30
MYADM F: 50-GTGGCTCAATCCGTCTCCA-30 2.0
R: 50-GATGGTGGTGCGGGTTACC-30
HR F: 50-CAAGGATGTGGACTCGGGA-30 1.5
R: 50-CAGTTTTGCAGGGAGAGCCA-30
FLJ10349 F: 50-GCCACCATGCTGCACGT-30 1.5
R: 50-GTGGTCAAGCAGGTAGGAGAGG-30
ARF4 F: 50-CCCTCTTCTCCCGACTATTTGG-30 1.5
R: 50-ATTGGTGGTGACTATCTCCCCTAAC-30
CTSL F: 50-CTGTAGCAGTGAAGACATGGATCA-30 1.5
R: 50-CGTAGCCACCCATGCCC-30
PGK1 F: 50- TAAAGGGAAGCGGGTCGTT-30 1.5
R: 50-GTGGCTCATAAGGACTACCGACTT-30
CKS2 F: 50-CGCTCTCGTTTCATTTTCTGC-30 1.5
R: 50-TGGAAAGTTCTCTGGGTAACATAACA-30
CDKN3 F: 50-TACAACCTGCCTTAAAAATTACCGA-30 1.5
R: 50-GACAGGTATAGTAGGAGACAAGCAGCT-30
NCK2 F: 50-GGCTATGTACCGTCCAACTACG-30 1.5
R: 50-GCTGGTCTTCCTGCGC-30
ITGB5 F: 50-GAGGAAGTGTGAGGGTCTGAAGA-30 1.5
R: 50-TGACCCCCACCTCCAGGCT-30
UBE2S F: 50-CCAGGTCACCATCGAGGG-30 1.5
R: 50-CTTCCCCAGCAGGAGTTTCA-30
DUSP6 F: 50-CCTTCCTTCCCAGTGGAGATC-30 2.0
R: 50-CTCAAAGAGATTCGGCAAATTGG-30
GDF15 F: 50-CGAAGACTCCAGATTCCGAGAG-30 1.5
R: 50-CCAGCCGCACTTCTGGC-30
GAPDH F: 50-CGACAGTCAGCCGCATCTT-30 1.5
R: 50-GCCCAATACGACCAAATCCG-30
b-Actin F: 50-CGTGCTGCTGACCGAGG-30 1.5
R: 50-GCAACGTACATGGCTGGGG-30
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immunohistochemical staining. Therefore, cells were cultured to
70–80% confluency on Lab-Tek
sII 8 Chamber slides (Nalge Nunc
International Corp., Naperville), followed by fixation in acetone for
10min. Prior to staining for THBD, GFD15 and FABP7, AgarCyto
sections as well as cultured cells were subjected to a 20-min
preincubation using 20% normal horse serum and 20% normal
goat serum (Vector Laboratories, Burlingame, CA, USA), respec-
tively. The sections/cells were stained in a three-step procedure
utilising the following incubations: overnight incubation at 41C
with mouse monoclonal antibodies against THBD (DAKO-TM
1009) (DakoCytomation B.V., Heverlee, Belgium), rabbit poly-
clonal antibodies against GDF15 (US Biological, ImmunoSource,
Zoersel-Halle, Belgium) or rabbit polyclonal antibodies against
FABP7 (Cell Sciences Inc., Canton, MA, USA), diluted 1:50, 1:600
and 1:7500 in PBS, respectively. Thereafter, the sections/cells were
incubated with a biotinylated horse-anti-mouse or goat-anti-rabbit
antiserum for 30min, followed by a 45-min incubation with
peroxidase-labelled avidin-biotin complex (Vector Laboratories).
Between all incubations, slides were washed three times in PBS.
3-amino-9-ethylcarbazole was used as substrate to visualise the
bound antibodies. After counterstaining with Mayers haematox-
ylin, sections were mounted with Imsol.
Western blotting
1F6 and Mel57 cells were solubilised using RIPA buffer (PBS, 1%
Nonidet P40, 0.5% sodiumdeoxycholate, 0.1% SDS) containing
Completet, mini Protease Inhibitor Cocktail (Roche Diagnostics
GmbH) and 2mM PMSF. Equal amounts of proteins (40mg total
cell lysate) were then separated on a 15% SDS polyacrylamide gel
under reducing conditions. Subsequently, proteins were electro-
phoretically transferred onto a nitrocellulose membrane (Hybond
ECL, Amersham Biosciences) in blot buffer (25mM Tris pH 8.6,
0.2 M glycin and 20% methanol). Blots were incubated for 1h in
0.5  blocking buffer (LI-COR Biosciences, Bad Homburg,
Germany)/PBS at room temperature, followed by an overnight
incubation at 41C with specific primary antibodies against GDF15
(see Immunohistochemistry section), diluted 1:1000 in blocking
solution (0.5  blocking buffer/PBS/0.05% Tween-20). After
washing with PBS-T, blots were incubated for 1h with goat-anti-
rabbit-IRDyet 800 infrared dye secondary antibodies (Rockland
Immunochemicals Inc., Gilbertsville, PA, USA; dilution 1:2000 in
blocking solution) under dark conditions, at room temperature.
Then blots were scanned using the Odyssey Infrared Imager
(LI-COR Biosciences).
RESULTS
Differential gene expression in human melanoma cell lines
1F6 and Mel57
The genes/ESTs that were spotted on our custom oligonucleotide
array, were previously found to be differentially expressed in
human melanoma cell lines 1F6 and Mel57 by using Affymetrix
Hu6800 and Hu35K arrays (de Wit et al, 2002). To determine
whether previous Affymetrix results could be reproduced using
our custom made oligonucleotide arrays, we first performed a dye-
swap experiment using Cy3 and Cy5 labelled cDNA of cell lines 1F6
and Mel57 as target probes for hybridisation. After scanning, we
found that 20% (n¼59) of the spots were not analysable. This was
most probably due to insufficient quality of the oligo’s, hybridisa-
tion efficiency and/or low copy expression of the genes in question.
Of the 80% (n¼239) that could be analysed, 98% (n¼235) of the
spots demonstrated differential gene expression that was identical
to previous Affymetrix results. This showed that Affymetrix results
were highly reproducible using our custom oligonucleotide array.
The indirect labelling method, which includes linear ampli-
fication of RNA, provided the opportunity to perform array
analyses using a reduced amount of starting material. To
determine validity of linear RNA amplification, target probes of
cell lines 1F6 and Mel57 were prepared using this alternative
labelling method and these probes were again hybridised to
our custom arrays in a dye-swap experiment. Scanning of the
arrays revealed that 58% (n¼172) of the spots could be analysed,
of which 99% (n¼170) showed similar differential gene expres-
sion as was previously found by Affymetrix array analyses.
Compared with the custom array experiment using the direct
labelling method, we found that 91% (n¼157) of the analysable
genes showed a similar expression pattern and only one of
these genes showed an aberrant differential expression than was
found by Affymetrix arrays. Although our results demonstrated
that a reduced number of spots could be analysed for differential
gene expression using the indirect labelling method, the re-
producibility of previous Affymetrix array results remained very
high.
Differential gene expression in human melanocytic lesions
As human melanoma cell lines 1F6 and Mel57 display different
metastatic behaviour after subcutaneous inoculation into nude
mice (Westphal et al, 1997), we reasoned that the genes that were
found to be differentially expressed in these cell lines could well be
involved in melanocytic tumour progression, especially in meta-
static processes. To determine whether differential expression of
these genes could also be detected in human melanocytic tumour
lesions, we performed custom array analyses using target probes
derived from NN and MM tissue samples. These NN and MM
lesions contained a minimal tumour percentage of 50 and 60%,
respectively. After Cy3 and Cy5 labelling of the probes using the
indirect labelling method, individual NN and MM samples were
hybridised in eight independent dye-swap experiments. Addition-
ally, pooled samples of these NN (n¼6) and MM lesions (n¼6)
were used to perform a dye-swap experiment. Compared to
hybridisation experiments using cell line material, overall in the
dye-swap experiments using melanocytic lesions, a lower percen-
tage of the spots could be analysed, namely 15–40% (n¼45–119).
This can be explained by the considerably lower quality of total
RNA of the lesions, influencing the labelling efficiency. In first
instance, we determined differential expression only by visual
analysis and by comparing the F-B values of the Cy dyes (GenePix
Pro 4.0 software). In total, 42 genes/ESTs showed a highly
reproducible differential gene expression, meaning similar results
in more than five out of nine experiments. Although all of these
genes might be candidate players in tumour progression, in this
study we further focused on the 25 genes that showed comparable
results in eight out of nine or even nine out of nine experiments
(Table 2). For genes with similar differential expression in eight
out of nine dye-swaps, we mostly found no detectable differential
expression in the remaining experiment (no fluorescence signal or
equal intensities for Cy3 and Cy5) and occasionally a swift in
differential expression in NN and MM lesions (i.e. THBD,
D4S234E, CTSL and GDF15).
To obtain an indication of the fold change of the differential
gene expression, we also calculated the log2 of the median of ratios
for the dye-swap experiments. Table 3 shows an example of these
values for the dye-swap experiment using pooled NN and MM
samples. For most of the genes, comparable fold changes could be
determined within one dye-swap experiment, indicating the high
reproducibility of the dye-swap arrays. However, log2 values were
not always in accordance with data demonstrated in Table 2, as for
instance is seen for NCK2 and ITGB5 genes in Table 3. Moreover,
comparing all dye-swap experiments, we saw that although the
differential expression in NN and MM was highly similar for
the genes, the fold changes were quite variable. This suggests that
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same when comparing different individual NN and MM lesions.
To determine whether among the 298 genes that were present
on the array, differential gene expression also could be analysed
in melanocytic tumour lesions of similar progression stages, we
performed a dye-swap experiment using two different NN samples.
Only eight genes showed differential expression, of which TYRP1
was one of them. The other seven genes did not belong to the
group that showed differential gene expression comparing NN and
MM in more than five dye-swap experiments. These eight genes
most probably represent patient-specific and/or pigment-related
differences in gene expression.
Verification of differential gene expression
To validate the differential gene expression we found by custom
array analysis, we performed semiquantitative RT–PCR for the
25 genes indicated in Table 2. We first looked at their differential
expression found in melanoma cell lines 1F6 and Mel57 (Figure 2).
Using GAPDH and b-actin for normalisation, we determined that
differential expression could be corroborated for all genes, except
for MYL6 and FLJ10349. PGK1, which was initially selected as
housekeeping gene, showed indeed no differential expression in
the melanoma cell lines. By performing immunohistochemistry
(IHC) on AgarCyto’s of 1F6 and Mel57, we wanted to determine
whether differential expression could also be detected on the
protein level. Unfortunately, antibodies were only limitedly
available. Nevertheless, IHC using THBD, GDF15 and FABP7
specific antibodies showed that a similar differential protein
expression could be detected as was seen for their mRNA
expression by array analyses and semiquantitative RT–PCR
(Figure 3). Figure 3C and D shows that THBD was mainly localised
to the cell membrane in 1F6 cells, whereas Mel57 cells were
completely negative. For GDF15 the difference in protein expres-
sion was less distinctive; however, an upregulated cytoplasmic
expression could be detected in cell line Mel57 compared to 1F6
(Figure 3E and F). FABP7 showed a significant higher cytoplasmic
protein expression in 1F6 than could be detected in Mel57 (Figure
3G and H). Next to AgarCyto’s, also slides containing cultured 1F6
and Mel57 cells were stained for THBD, GDF15 and FABP7. These
cultured cells showed comparable staining results as were found
with IHC on AgarCyto’s. Even though the observed differences in
protein expression for FABP7 and especially for GDF15 were a
little less profound in the cultured cells (data not shown), THBD
again showed a marked expression in 1F6, whereas Mel57 cells
remained negative (Figure 3I and J). The differential protein
expression of GDF15 could be better visualised by Western blot
analysis as is demonstrated in Figure 3K. In this figure, the 35kDa
band represents the pro-form of GDF15 (propeptideþmature
protein), whereas the 25kDa band shows the cleaved GDF15
propeptide. The mature form of GDF15 (10kDa) could hardly be
detected by Western blotting using cell lysates as this protein is
secreted by the cells.
Also for human melanocytic tumour lesions, semiquantitative
RT–PCR was used to verify differential gene expression. As only a
limited amount of cDNA was available of most lesions, a pilot
experiment was performed in which differential expression of the
25 genes listed in Table 2 was determined in two samples of NN,
atypical nevi (AN), primary melanoma (PM) and MM. This
experiment showed that 12 of the 25 genes displayed distinct
differential expression during melanoma progression (data not
shown). These 12 genes were selected for further expression
profiling in a larger series of melanocytic tumour lesions. For all
12 genes, the relative expression to GAPDH was determined as
is demonstrated for FABP7 in Figure 4A. Figure 4B shows the
graphical representation of the relative expression of these 12
genes during melanoma progression. For MYL6 and C7orf20, no
distinct differential expression could be detected in this larger
series and CTSL showed an inversed differential expression by
semiquantitative RT–PCR than was found by custom array
analyses. In accordance with our array data, downregulation of
THBD, FABP7, H2AFJ, RRAGD, MYADM and HR and upregula-
tion of CKS2, NCK2 and GDF15 was seen in MM compared to NN
lesions. The upregulation of CKS2, NCK2 and GDF15 seemed to
follow a somehow gradual course during melanocytic tumour
progression, whereas downregulated expression of THBD, FABP7,
RRAGD, MYADM, HR and especially H2AFJ was more predomi-
nantly restricted to MM lesions. To exclude that differential
expression was significantly influenced by the presence of
keratinocytes in the NN, AN and PM lesions, we performed
semiquantitative RT–PCR on two normal skin (NS) and laser
dissected melanocytic cells derived from two NN lesions. Only for
C7orf20 and MYADM, we found that the presence of keratinocytes
most probably caused the differential expression seen by array
analyses and RT–PCR. Overall, it has to be noted that for some
differentially expressed genes no PCR product could be detected
after 35 cycles, meaning that expression of these genes might even
be stronger downregulated in the melanocytic tumour lesions than
is demonstrated in Figure 4B.
To strengthen our semiquantitative RT–PCR results and more
precisely quantify the differences found in expression, we
performed real-time qRT–PCR for two randomly selected genes,
namely FABP7 and GDF15. We first determined fold change of
differential expression between cell line 1F6 and Mel57. A 24-fold
increase of FABP7 expression was found in 1F6 compared to
Mel57; for GDF15 a 10-fold decrease was detected. Figure 5
demonstrates the expression of FABP7 and GDF15 in melanocytic
tumour lesions relative to 1F6 and Mel57, respectively. qPCR
results were highly similar to our data derived from custom array
analyses and semiquantitative RT–PCRs. For FABP7 a decreased
expression could again be determined when comparing MM
lesions to NN lesions. The opposite was true for GDF15. During
tumour progression, we found that down- or upregulated
expression of FABP7 and GDF15, respectively, could already be
detected in PM lesions, but was most prominent in MM. Moreover,
NS and laser dissected NN samples (NN#) that were included in
this qPCR ensured that keratinocytes did not influence the
differential gene expression of FABP7 and GDF15 in NN and
MM lesions. As for some tumour samples again no PCR product
could be detected after 40 cycles, downregulated expression shown
in Figure 5 might probably be underestimated.
To provide an indication of the overall fold change of FABP7
and GDF15 differential expression in NN and MM lesions, we
calculated the average relative expression of NN and MM samples
obtained by qPCR and compared these values. We found a 164-
fold downregulation of FABP7 expression in MM compared to
NN, whereas GDF15 showed a 53-fold upregulated expression.
These fold changes are much higher than those found by custom
array analyses (Table 3).
DISCUSSION
In this study, custom made oligonucleotide arrays were designed,
based on previous Affymetrix high-density oligonucleotide array
results, in which differential expression was analysed in human
melanoma cell lines 1F6 and Mel57 (de Wit et al, 2002). The highly
comparable results obtained by both array techniques, concerning
differential gene expression in 1F6 and Mel57, indicate that our
custom arrays are a reliable tool for analysis of differential gene
expression.
Previous studies already showed that linear RNA amplification
provides the opportunity to perform array analysis with minute
amounts of starting material (Puskas et al, 2002; Gomes et al, 2003;
Klur et al, 2004; Schneider et al, 2004). We experienced that the
indirect labelling method, which is based on linear RNA
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sTable 2 Differential gene expression between NN and MM samples determined by dye-swap array experiments
Experiment no. 
9** 
Up-regulation  
(# experiments)  UniGene 
ID  Gene name  Gene 
symbol 
NN MM NN MM NN MM NN MM NN MM NN MM NN MM NN MM NN MM  NN  MM 
2030 Thrombomodulin  THBD                                    8/9 1/9 
405913  Llikely ortholog of mouse gene rich cluster, C10  GRCC10                                      9/9 0/9 
26770  Fatty acid binding protein 7, brain  FABP7  ND ND                                  8/9 0/9 
36727  H2A histone family, member J  H2AFJ                                      9/9 0/9 
75219  Tyrosinase-related protein 1  TYRP1                                      9/9 0/9 
77385  Myosin, light polypeptide 6, alkali  MYL6                         ND  ND         8/9 0/9 
79404  DNA segment on chromosome 4, 234 expressed seq  D4S234E                                    8/9 1/9 
446471 CD74  antigen  CD74  ND ND                                  8/9 0/9 
107387  Chromosome 7 open reading frame 20  C7orf20                     ND  ND             8/9 0/9 
415997  Collagen, type VI, alpha 1 precursor  COL6A1  ND ND                                  8/9 0/9 
184542 Yippee  protein  CGI-127         ND  ND                          8/9 0/9 
238679  Ras-related GTP binding D  RRAGD     ND  ND                             8/9 0/9 
380906 Myeloid-associated  differentiation  marker  MYADM                                      9/9 0/9 
272367 Hairless  homolog  (mouse)  HR                                      9/9 0/9 
19333  Hypothetical protein FLJ10349  FLJ10349          ND ND                          0/9 8/9 
435639  ADP-ribosylation factor 4  ARF4                                      0/9 9/9 
418123  Cathepsin L precursor (Major excreted protein)   CTSL                                    1/9 8/9 
78771 Phosphoglycerate  kinase  1  PGK1                                      0/9 9/9 
83758  CDC28 protein kinase regulatory subunit 2  CKS2                                      0/9 9/9 
84113  Cyclin-dependent kinase inhibitor 3  CDKN3                      ND ND              0/9 8/9 
101695 NCK  adaptor  protein  2  NCK2  ND ND                                  0/9 8/9 
149846 Integrin,  beta  5  ITGB5  ND ND                                  0/9 8/9 
396393  Ubiquitin carrier protein E2  UBE2S          ND ND                          0/9 8/9 
298654  Dual specificity protein phosphatase 6 (MAPKP3)  DUSP6      ND ND                              0/9 8/9 
296638 Growth  differentiation factor 15 (NAG-1 / MIC-1)  GDF15                                    1/9 8/9 
1* 2* 3* 4* 5* 6* 7* 8*
NN¼nevus nevocellularis; MM¼melanoma metastasis; *dye-swap experiment using individual NN and MM samples; **dye-swap experiment using pooled NN and MM samples; black boxes¼upregulated expression was detected
in dye-swap experiment; ND¼no differential expression could be detected in dye-swap experiment. Differential gene expression was determined by visual analysis and by comparing the F-B values of Cy3 and Cy5 dyes.
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sTable 3 Fold changes of differentially expressed genes in a dye-swap experiment using pooled NN and MM samples
log2 of median of ratios (Cy5/Cy3)*  UniGene 
ID  Gene name  Gene 
symbol 
NN_Cy5 / MM_Cy3 NN_Cy3 / MM_Cy5 
2030 Thrombomodulin  THBD  _0.72  ±  0.09  _1.35  ±  0.08 
405913  Likely ortholog of mouse gene rich cluster, C10  GRCC10  _1.42  ±  0.10  _1.07  ±  0.34 
26770  Fatty acid binding protein 7, brain  FABP7  _2.55  ±  0.15  _1.89  ±  0.11 
36727  H2A histone family, member J  H2AFJ  _3.36  ±  0.33  _2.73  ±  0.21 
75219  Tyrosinase-related protein 1  TYRP1  _1.81  ±  0.27  _0.87  ±  0.42 
77385  Yosin, light polypeptide 6, alkali  MYL6  _0.68  ±  0.16  _1.69  ±  1.16 
79404  DNA segment on chromosome 4, 234 expressed seq  D4S234E  _0.77  ±  0.15  _0.64  ±  0.19 
446471  CD74 antigen   CD74  _0.50  ±  0.07  _0.52  ±  0.16 
107387  Chromosome 7 open reading frame 20  C7orf20  _0.45  ±  0.12  _0.65  ±  0.12 
415997  Collagen, type VI, alpha 1 precursor  COL6A1  _1.23  ±  0.14  _0.67  ±  0.10 
184542 Yippee  protein  CGI_127  _0.78  ±  0.09  _1.63  ±  0.24 
238679  Ras-related GTP binding D   RRAGD  _0.88  ±  0.12  _1.45  ±  0.13 
380906  Myeloid-associated differentiation marker   MYADM  _1.80  ±  0.19  _1.47  ±  0.07 
272367  Hairless homolog (mouse)  HR  _2.04  ±  0.14  _1.89  ±  0.17 
19333  Hypothetical protein FLJ10349  FLJ10349  _0.81  ±  0.12  _0.67  ±  0.10 
435639  ADP-ribosylation factor 4   ARF4  _1.62  ±  0.08  _1.05  ±  0.20 
418123  Cathepsin L precursor (Major excreted protein)   CTSL  _0.63  ±  0.12  _0.90  ±  0.14 
78771  Phosphoglycerate kinase 1  PGK1  _0.95  ±  0.05  _0.69  ±  0.16 
83758  CDC28 protein kinase regulatory subunit 2  CKS2  _2.10  ±  0.04  _2.60  ±  0.25 
84113  Cyclin-dependent kinase inhibitor 3   CDKN3  _1.83  ±  0.14  _3.29  ±  0.43 
101695  NCK adaptor protein 2  NCK2   ND  _0.91  ±  0.23 
149846  Iintegrin, beta 5  ITGB5    ND  _0.38  ±  0.08 
396393  Ubiquitin carrier protein E2  UBE2S  _1.37  ±  0.07  _2.66  ±  0.24 
298654  Dual specificity protein phosphatase 6 (MAPKP3)  DUSP6  _1.10  ±  0.18  _0.40  ±  0.27 
296638  Growth differentiation factor 15 (NAG-1 / MIC-1)  GDF15  _1.78  ±  0.07  _2.15  ±  0.38 
_4 _3 _2 _10 1 2 3 4 234
NN¼nevus nevocellularis; MM¼melanoma metastasis; *median of ratios values (GenePix Pro 4.0) were transformed by taking the log2 and averaged from octaplicate gene-specific spots (mean7s.d.); ND¼no detectable differential
expression by analysis of log2 of median of ratios.
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Genetics and Genomicsamplification, is indeed a valuable and reliable technique, although
we determined a reduction in number of analysable spots. This
might be explained by lack of optimal amplification efficiency, as
the quality of total RNA can negatively influence the procedure.
However, we found that signal intensities of the spots that could
be analysed were generally hardly diminished. Besides linear RNA
amplification by in vitro transcription (IVT), alternative methods
have recently been described to reduce the amount of staring
material for array analysis. For instance, amplification of full-
length double-stranded cDNA by PCR has been shown to be useful
in various studies (Saghizadeh et al, 2003; Becker et al, 2004;
Rihl et al, 2004), and also application of single-stranded linear
amplification protocol (SLAP) has been reported, which combines
linear amplification and PCR (Stirewalt et al, 2004). However, it
has to be noted that for identification of differential gene
expression by array analysis, it is highly preferable that each
sample is equally treated prior to hybridisation, as every
amplification method has the possibility to introduce transcript-
dependent biases, which even increase as the starting amount of
RNA decreases (Stirewalt et al, 2004).
Using fresh NN and MM lesions for custom array analyses, we
determined whether the differential gene expression that was
previously found in melanoma cell lines 1F6 and Mel57 could also
be detected in the in vivo situation. Differential gene expression
was analysed in two ways: by comparing F-B values of the Cy dyes
and by calculating the log2 of the median of ratios for each dye
swap experiment. For the latter method, which provided an
indication of the fold change of the differential gene expression,
the ‘median of ratios’ was chosen over the commonly used ‘ratio of
medians’ as Brody et al (2002) determined that the ‘median of
ratios’ provided a more consistent measurement. However, as the
size of the spots still influences the accuracy of the measurement of
the ‘median of ratios’ values (Brody et al, 2002), in our study we
attached higher importance to the F-B software analysis. Moreover,
comparison of F-B values of the Cy dyes showed a better
correlation with visual analysis of the arrays. In this way, 25 genes
were identified showing a highly reproducible constant differential
expression pattern in NN vs MM lesions. The dye-swap experiment
using two NN samples for hybridisation showed that the
differential expression of most of these genes was not patient
specific.
For nine of the 25 genes, namely THBD, FABP7, H2AFJ, RRAGD,
MYADM, HR, CKS2, NCK2 and GDF15, our semiquantitative
RT–PCR results were in accordance with the differential expres-
sion that was found by custom array analyses. However, the
possibility remains that for some of the 13 genes that were now
only tested in a pilot experiment using semiquantitative RT–PCR,
verification of differential expression can still be achieved using an
expanded series of melanocytic tumour lesions. For instance,
DUSP6 was very recently also found to be differentially expressed
in normal melanocytes compared to melanoma cells by Hoek et al
(2004). This indicates it might be an interesting gene for further
studies. Additionally, also genes that showed a differential
expression in five out of nine, six out of nine and seven out of
nine custom array experiments might still be potential players in
melanocytic tumorigenesis.
Real-time qPCR, performed for FABP7 and GDF15, strengthened
the data of our semiquantitative RT–PCR analyses, as both
techniques provided comparable results. Moreover, it confirmed
differential gene expression found by custom array analysis,
although fold changes that were found by performing qPCR were
much higher than those obtained using arrays (log2 of the median
of ratios, Table 3). The tendency to underestimate fold change
ratios by array analysis is also reported in other studies (Rajeevan
et al, 2001; Yuen et al, 2002).
Our differential gene expression data showed minimal overlap
with previously described microarray experiments in which also
gene expression patterns were studied in cutaneous melanoma
progression (Brem et al, 2001; Baldi et al, 2003b; Carr et al, 2003;
Dooley et al, 2003; Rumpler et al, 2003; Becker et al, 2004; Nambiar
et al, 2004). This could be explained by the fact that design of
our custom made oligonucleotide arrays was based on previously
found differential gene expression in melanoma cell lines. This
way, we already made a considerable selection of genes to be
examined for differential gene expression, probably missing some
genes that might also be involved in melanocytic tumour
progression. Moreover, high variability can be introduced between
related array studies, as arrays designed with different types of
oligonucleotides/cDNAs (e.g. 50-/60-/70-mer oligo’s, full-length
cDNA) can be used and distinct methods can be selected
for labelling of target probes. Therefore, numerous comparable
microarray studies are described with different outcomes
(Nambiar et al, 2004). This emphasises the necessity of verification
of the array data using more conventional techniques, like (semi-)
quantitative RT–PCR, to prove that differential gene expression is
really present.
Until now, minimal information is available in literature of most
of the genes that we found differentially expressed by our custom
array analyses as well as by RT–PCR. However, GDF15 and THBD
were previously described to be involved in tumorigenesis. GDF15,
which is also called macrophage inhibitory cytokine-1 (MIC-1),
NSAID-activated protein (NAG-1) or prostate differentiation factor
(PLAB), is a divergent member of the tumour growth factor b
(TGF-b) superfamily (Bootcov et al, 1997; Hromas et al, 1997; Baek
et al, 2001). The major function of GDF15 is still uncertain, but
there are indications that it plays a role in growth inhibition and
induction of apoptosis in several tumour cell lines (Li et al, 2000;
Albertoni et al, 2002; Yang et al, 2003). Controversially however,
several studies have reported an upregulated (secreted) expression
in (advanced and more aggressive) tumours compared to
noncancerous tissues or less aggressive tumours (Welsh et al,
2001; Brown et al, 2003; Karan et al, 2003; Nakamura et al, 2003).
This is in accordance with our data, as we also found an
upregulated expression during melanoma progression. THBD is a
thrombin receptor, which is mostly found on the surface of
vascular endothelial cells and epidermal keratinocytes. However,
its presence is also reported on tumour cells of several types of
cancer, such as, hepatocellular carcinoma, ovarian cancer, breast
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Figure 2 Verification of differential gene expression in human melanoma cell lines 1F6 and Mel57 by semiquantitative RT–PCR. Differential gene
expression was determined by normalisation for b-actin and GAPDH. For nearly all of the 25 genes that were tested, differential expression that was found
by custom array analyses could be validated by semiquantitative RT–PCR, except for MYL6 and FLJ10349.
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Figure 3 Analysis of protein expression of THBD, GDF15 and FABP7 in human melanoma cell lines 1F6 and Mel57. Magnification ( 400) of AgarCyto’s
(A–H) and cultured 1F6 and Mel57 cells (I, J). (A, B) Negative control of 1F6 and Mel57, respectively, leaving out specific antisera. (C, D, I, J) IHC using
THBD specific antibodies; in AgarCyto’s as well as cultured cells most 1F6 cells showed a (membranous) THBD specific staining (C, I), whereas Mel57 cells
were completely negative (D, J). (E, F) IHC using GDF15 specific antibodies; a more intense cytoplasmic GDF15 staining could be detected in cell line
Mel57 (F), compared to 1F6 cells (E). (G, H) IHC using FABP7 specific antibodies; 1F6 cells showed a higher immunoreactivity for FABP7 (cytoplasmic) (G)
than Mel57 cells (H). (K) Western blot analysis of GDF15; a distinct preferential protein expression could be detected in Mel57 compared to 1F6. The
35kDa band represents the pro-form of GDF15 (pro-peptideþmature protein), whereas the 25kDa band shows the cleaved GDF15 pro-peptide.
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scancer and squamous cell carcinoma (Suehiro et al, 1995; Kim
et al, 1997; Tabata et al, 1997; Wilhelm et al, 1998). In these
tumours, the expression level of THBD is inversely correlated with
malignancy of cancer. As for melanoma, it was previously reported
that THBD isolated from human urine could suppress experi-
mental lung metastasis of murine melanoma cells (B16F10 cells) in
mice and it inhibited invasion of these cells in vitro (Hosaka et al,
2000). Also for human melanoma cell lines, a negative correlation
was described between THBD expression and cell proliferation in
vitro and in vivo (Zhang et al, 1998). This is in accordance with our
findings, as we determined a downregulated THBD expression in
MM lesions by array analysis and RT–PCR. Moreover, our IHC
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Figure 4 Verification of differential gene expression in human melanoctyic tumour progression lesions by semiquantitative RT–PCR. (A) For 12
differentially expressed genes, relative expression to GAPDH was determined by semiquantitative RT–PCR as shown for FABP7. (B) For MYL6 and
C7orf20 differential expression could hardly be detected. THBD, FABP7, H2AFJ, RRAGD, MYADM and HR showed a downregulated expression during
melanoma progression, with a preferable decrease in MM lesions. The latter was especially true for H2AFJ. Expression of CKS2, NCK2 and GDF15 showed
an upregulation associated with increased malignancy of melanocytic tumour lesions. For THBD, FABP7, H2AFJ, RRAGD, MYADM, HR, CKS2, NCK2 and
GDF15 differential expression found by semiquantitative RT–PCR was in accordance with our custom array data, whereas CTSL showed an inverse
differential expression.
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sdata showed membranous expression in human melanoma cell line
1F6, whereas the more malignant cell line Mel57 remained
negative. Although, previous studies report THBD expression in
keratinocytes, our RT–PCR data of NS and laser dissected
melanocytic NN cells indicated that epidermal cells were not
responsible for the differential expression that we determined in
NN and MM lesions. Obviously, for both GDF15 and THBD,
additional studies are necessary to elucidate their role in cancer
biology and determine its potential clinical significance.
In summary, this study provides a reliable, solid indication that
CKS2, NCK2, GDF15 THBD, FABP7, RRAGD, MYADM, HR and
H2AFJ are candidate players in melanocytic tumour progression,
as similar differential expression patterns are demonstrated for
these genes by custom array analysis, semiquantitative RT–PCR
and even real-time qPCR. The genes that showed a preferable
expression in benign melanocytic tumour stages and loss of
expression during tumour progression might be functional
markers to facilitate early diagnosis of melanocytic lesions before
onset of the metastatic phase. Genes with an elevated expression in
advanced, more malignant melanocytic lesions are probably more
suitable for development of novel therapeutics for melanoma
patients. Moreover, regarding prognostic settings, the down-
regulated genes can be potential indicators for a relatively good
prognosis, whereas the upregulated genes might be of opposite
prognostic value. Nevertheless, to ensure that the genes that we
found to be differentially expressed in this study are indeed useful
for diagnostic, prognostic and/or therapeutical applications,
further investigation is necessary.
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Figure 5 Verification of differential gene expression of FABP7 and GDF15 in human melanoctyic tumour progression lesions by real-time qPCR. For
FABP7 as well as GDF15, GAPDH was used for normalisation. FABP7 expression in melanocytic tumour lesions is demonstrated relative to expression in
cell line 1F6. A downregulated FABP7 expression was detected during melanocytic tumour progression, which was most prominent in MM lesions. For
GDF15, expression in melanocytic tumour lesions is demonstrated relative to expression in cell line Mel57. GDF15 showed an upregulated expression in
malignant stages of melanocytic tumour progression. Inclusion of normal skin (NS) tissue and laser dissected melanocytes derived from NN lesions (NN#)
in the real-time qPCR analyses revealed that epidermal cells do not significantly influence the differential gene expression of FABP7 and GDF15 that is seen in
NN and MM lesions.
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